OR WAIT 15 SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
January 11, 2021
Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.
January 05, 2021
The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
November 24, 2020
According to an abstract presented during the 2020 Virtual Retina Society Annual Meeting, women are 34% less likely to receive a repair for a retinal detachment compared with men.
November 23, 2020
Thanks to researchers like Russell N. Van Gelder, MD, PhD, the possibility of restoring sight to people blinded by age-related macular degeneration or retinitis pigmentosa is another step closer to reality.
November 15, 2020
Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.
Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.
Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
November 14, 2020
During AAO 2020, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.